KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Gross Margin (2019 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Gross Margin for 8 consecutive years, with 82.22% as the latest value for Q1 2026.

  • For Q1 2026, Gross Margin rose 21616.0% year-over-year to 82.22%; the TTM value through Mar 2026 reached 81.0%, down 94.0%, while the annual FY2025 figure was 81.77%, 460.0% down from the prior year.
  • Gross Margin hit 82.22% in Q1 2026 for Alnylam Pharmaceuticals, up from 75.6% in the prior quarter.
  • Across five years, Gross Margin topped out at 89.8% in Q2 2024 and bottomed at 133.94% in Q1 2025.
  • Average Gross Margin over 5 years is 71.62%, with a median of 84.21% recorded in 2025.
  • Year-over-year, Gross Margin plummeted -22290bps in 2025 and then surged 21616bps in 2026.
  • Alnylam Pharmaceuticals' Gross Margin stood at 86.22% in 2022, then dropped by -3bps to 83.63% in 2023, then dropped by -1bps to 82.69% in 2024, then dropped by -9bps to 75.6% in 2025, then increased by 9bps to 82.22% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods came in at 82.22%, 75.6%, and 84.21% for Q1 2026, Q4 2025, and Q3 2025 respectively.